Guggenheim Capital LLC Intellia Therapeutics, Inc. Transaction History

Guggenheim Capital LLC

  • $14 Billion
  • Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 66,947 shares of NTLA stock, worth $957,342. This represents 0.01% of its overall portfolio holdings.

Number of Shares
66,947
Previous 61,266 9.27%
Holding current value
$957,342
Previous $1.37 Million 0.29%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$19.72 - $27.36 $112,029 - $155,432
5,681 Added 9.27%
66,947 $1.38 Million
Q2 2024

Aug 14, 2024
SELL
$20.02 - $27.22 $44,624 - $60,673
-2,229 Reduced 3.51%
61,266 $1.37 Million
Q1 2024

May 14, 2024
BUY
$23.82 - $32.8 $54,809 - $75,472
2,301 Added 3.76%
63,495 $1.75 Million
Q4 2023

Feb 14, 2024
SELL
$23.16 - $32.34 $242,855 - $339,117
-10,486 Reduced 14.63%
61,194 $1.87 Million
Q3 2023

Nov 14, 2023
SELL
$31.62 - $45.78 $473,098 - $684,960
-14,962 Reduced 17.27%
71,680 $2.27 Million
Q2 2023

Aug 11, 2023
BUY
$34.58 - $46.03 $133,962 - $178,320
3,874 Added 4.68%
86,642 $3.53 Million
Q1 2023

May 10, 2023
SELL
$33.3 - $44.82 $128,771 - $173,318
-3,867 Reduced 4.46%
82,768 $3.08 Million
Q4 2022

Feb 14, 2023
BUY
$33.21 - $62.69 $497,386 - $938,908
14,977 Added 20.9%
86,635 $3.02 Million
Q3 2022

Nov 14, 2022
SELL
$53.92 - $71.7 $430,335 - $572,237
-7,981 Reduced 10.02%
71,658 $4.01 Million
Q2 2022

Aug 15, 2022
BUY
$38.49 - $76.21 $127,786 - $253,017
3,320 Added 4.35%
79,639 $4.12 Million
Q1 2022

May 16, 2022
BUY
$58.27 - $118.99 $284,182 - $580,314
4,877 Added 6.83%
76,319 $5.55 Million
Q4 2021

Feb 14, 2022
BUY
$100.76 - $138.36 $1.47 Million - $2.01 Million
14,563 Added 25.6%
71,442 $8.45 Million
Q3 2021

Nov 15, 2021
BUY
$132.37 - $176.78 $3.49 Million - $4.66 Million
26,388 Added 86.54%
56,879 $7.63 Million
Q2 2021

Aug 13, 2021
SELL
$60.88 - $161.91 $37,562 - $99,898
-617 Reduced 1.98%
30,491 $4.94 Million
Q1 2021

May 13, 2021
BUY
$46.59 - $83.68 $1.45 Million - $2.6 Million
31,108 New
31,108 $2.5 Million

Others Institutions Holding NTLA

# of Institutions
313
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email